HR-6166-119
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Frank Pallone (D-NJ)
What it does
This bill would do three things: (1) expand the Medicare drug price negotiation program from 20 to 50 drugs per year, require negotiators to consider international drug prices in six peer countries, and extend negotiated prices to private insurance plans that opt in; (2) apply Medicare inflation rebate penalties — which require drug manufacturers to pay rebates when prices rise faster than inflation — to commercial insurance markets, not just Medicare; and (3) cap annual out-of-pocket prescription drug costs at $2,000 for privately insured patients starting in 2027, and cap insulin copayments at $35 per 30-day supply across all private insurance plans. It would also repeal certain changes to the negotiation program made by a prior law (Public Law 119-21).
Who benefits
Privately insured patients with high prescription drug costs, particularly those with chronic conditions such as diabetes, cancer, rheumatoid arthritis, and multiple sclerosis who currently face costs well above $2,000 annually. The approximately 37 million Americans with diabetes who use insulin would benefit from the $35 cap. Medicare beneficiaries would benefit from a broader pool of negotiated drugs. Lower-income insured patients who currently ration medications due to cost. Employers and insurers that opt into negotiated prices may see reduced drug spending. Generic and biosimilar manufacturers face less direct competition from brand-name drugs whose prices are constrained.
Who is hurt
Brand-name pharmaceutical manufacturers would receive lower prices on more drugs and face inflation rebate penalties in commercial markets, potentially reducing revenue available for research and development. Pharmacy benefit managers (PBMs) could see reduced revenue from rebate arrangements on affected drugs. Insurers that do not opt into the negotiation program would be required to publicly disclose that decision, creating reputational and competitive pressure. Taxpayers and premium-payers could face higher premiums if insurers shift costs to offset the out-of-pocket cap. Patients using drugs not selected for negotiation would see no direct price benefit. Small and mid-size pharmaceutical companies with fewer blockbuster drugs may face disproportionate pressure relative to large manufacturers.
Supporters argue
Supporters argue that the U.S. pays two to four times more for the same brand-name drugs than peer nations such as Canada, Germany, and Australia, and that expanding negotiation to 50 drugs — up from 20 — would extend proven savings to millions more patients. They contend that the $2,000 out-of-pocket cap addresses a documented crisis in medication adherence, citing research showing that one in three Americans report not filling prescriptions due to cost. Extending inflation rebates to commercial markets, they argue, closes a loophole that allowed manufacturers to raise prices on privately insured patients even after Medicare penalties were imposed.
Opponents argue
Opponents argue that government-set price ceilings reduce the financial return on drug development, potentially deterring investment in new treatments — a concern supported by Congressional Budget Office analyses projecting that price negotiation could reduce the number of new drugs brought to market over time. They contend that the opt-in structure for private insurers is effectively coercive because public disclosure of non-participation creates market pressure that undermines genuine voluntariness. Critics also argue that capping out-of-pocket costs without addressing underlying list prices may simply shift costs to premiums, spreading the burden across all policyholders rather than reducing total spending.
Constitutional context
Congress's authority to regulate drug pricing in Medicare rests on the Taxing and Spending Clause (Art. I, §8, cl. 1), while extension of negotiated prices to private insurance markets relies on the Commerce Clause (Art. I, §8, cl. 3). The opt-in structure for private insurers — with mandatory public disclosure of non-participation — may raise questions about whether the disclosure requirement functions as a de facto mandate, echoing the Spending Clause coercion concerns raised in NFIB v. Sebelius (2012), though the mechanism here is market pressure rather than funding conditions. Post-Loper Bright (2024), any HHS implementing regulations would face independent judicial review rather than deferential scrutiny.
Checks and balances
Congress expands HHS's authority to negotiate drug prices and regulate private insurance cost-sharing; HHS is checked by judicial review of its implementing rules under the heightened post-Loper Bright standard, and private insurers retain a formal opt-out mechanism that limits the executive branch's direct control over commercial markets.
Historical precedent
The Inflation Reduction Act of 2022 established the original Medicare drug price negotiation program (capped at 10–20 drugs) and the $35 insulin cap for Medicare Part D; this bill would substantially expand both programs and extend them to the commercial insurance market for the first time.